Weekly thought on $AEMD, $CARA, $IBIO, $LRAD, $PI, $SIGO, TRXC

Meanwhile, I jumped back into $PI ’cause I don’t want to miss the continuing run-up when it happens. I bought back on Monday and added more on Tuesday when it corrected a bit. And off it went on Wednesday. I believe that the correction after the last earnings update was way oversold. There were talk of delayed order but the market reacted as if they were cancelled order. I can’t complain ’cause it gave me a chance to buy back $PI I’d been eyeing for a long long time ever since I missed the last run up to $60. There’s a future in RAIN RFID ’cause the technology can help remaining standing retailers to cut cost by managing inventory more effectively. Below is an excerpt from recent 3rd QTR 2017 earnings conference call:

Technology adoption tends to come in waves. For example, think mainframes to minicomputers to microcomputers, or first-generation mobile phones to flip-phones to smartphones. In RAIN, the first adoption wave was offline handheld inventory counting and purpose built RAIN software. Impinj leveraged that first wave to establish our industry-leading market position, but we chose not to build handheld readers or purpose built RAIN software. Instead, we predicted that a second adoption wave was coming, built on real-time fixed reading and enterprise software. For years we invested in fixed readers, gateways and our ItemSense operating system in enterprise software partnerships, our channel and our solutions go-to-market team, and in ubiquitous reading, all in anticipation of that second adoption wave.

I’m going to patiently wait for the second adoption wave to hit the beach, so to speak.

Next, I bought back into $CARA. I think it is time for this downtrodden stock to come back to life soon as we go into 2018.From the weekly chart above, you can see the technical divergence. See the upward slope of the yellow line in the MACD Histogram while the weekly candlestick bar is now bouncing off the 79 MA support. To me, this offer a good probability of a bounce coming soon.

$LRAD continues to hold its ground above $2. I think it’s a matter of time before the next wave of orders come in to take this stock to the mid-$2 level if not $3.

What more can I say about $SIGO except that the California green rush is going to take this one for a wild ride next year.The weekly chart above looks like it is ready to go up.

Production Capabilities Secured
Perhaps an indication of management’s expectations of eventual commercialization, in October Aethlon announced a formal collaboration with iBio, Inc (IBIO), a plant-based biopharmaceuticals company, to provide (as-needed) large-scale production of the plant-derived lectin (a recombinant form of Galanthus nivalis agglutin, or GNA) housed within the Hemopurifier cartridge that captures circulating viruses from the blood.

AEMD has noted that they completed a study with iBio, confirming their ability to produce GNA under cGMP. Per iBio’s website, their CDMO development and manufacturing facility, located near Houston, is capable of growing over four million plants as “in process inventory”. The large-capacity facility is also capable of meeting high production quotas which could be important, particularly in the event of high on-demand need such as, for example, if Hemopurifier was cleared for use as a countermeasure against certain pandemic outbreaks.

With IBIO’s plant-based large-scale production of the ingredients needed by the Hemopurifier being available and the fact that the company received Expedited Access Pathway Designation from FDA to accelerate U.S. Access to the Hemopurifier® as a treatment for life-threatening viruses, it’s mind-boggling that $AEMD is still available as such dirt cheap price for a biotech medical device stock.

And I haven’t even touched on the next mind-boggling potential for the Hemopurifier as potential treatment for cancer patients. Below is another excerpt from the same news above:

In October AEMD completed the initial milestone under the cancer-related Phase I grant that was awarded by NCI. We model the milestone, in the amount of approximately $75k, to be recognized as revenue in Q3. As a reminder, in September AEMD was awarded the Phase I grant funded by the National Cancer Institute. The contract, dubbed “Device Strategy for Selective Isolation of Oncosomes and Non-Malignant Exosomes” is for $299,250 and has a nine-month term. The University of Pittsburgh and Massachusetts General Hospital (researchers at Mass General were part of the tumor exosomes study discussed below) will work under AEMD to complete the contract which involves evaluation of AEMD’s technology in the capture of circulating tumor-derived exosomes. Upon successful completion, AEMD may be eligible for a Phase II grant that is expected to be worth approximately $1.5M.

If the capture of circulating tumor-derived exosomes resulted in saving patients dying of late stage metastasized cancers, this stock is going to be explosive!

$IBIO obviously is going to partake in AEMD success when it comes ’cause it is the main and sole supplier of AEMD’s Hemopurifier ingredients. We are all still waiting for the filing of IND for its IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. Also, a mind-boggling potential if successful in reversing fibrosis diseases. Can you imagine if both $AEMD and $IBIO go through the roof next year?

I’m still holding an adjusted core position of $TRXC. Although no longer a swing-for-the-fences position size, I’m still in to partake in any surprised announcement of Senhance sales. The company only received the FDA clearance a month ago so there is still time to expect surprised sales result.There is a daily bullish engulfment bar formed last Friday. So, we may see a bounce next week that may also break out of the yellow downtrend line to the upside. I’m expecting this one to be a volatile ride ahead.

Due to gain from $PI, $AEMD, and $CARA, my port gained back some for the week.